Cargando…
Rechallenge of denosumab in advanced giant cell tumor of the bone after atypical femur fracture: A case report and review of literature
Giant cell tumor of the bone (GCTB) is a locally aggressive neoplasm where surgery is often curative. However, it can rarely give rise to distant metastases. Currently, the only available active therapeutic option for unresectable GCTB is denosumab, an anti-RANKL monoclonal antibody that dampens the...
Autores principales: | Nasca, Vincenzo, Frezza, Anna Maria, Morosi, Carlo, Buonomenna, Ciriaco, Parafioriti, Antonina, Zappalà, Giorgio, Bini, Federica, Casali, Paolo Giovanni, Loppini, Mattia, Stacchiotti, Silvia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343706/ https://www.ncbi.nlm.nih.gov/pubmed/35928864 http://dx.doi.org/10.3389/fonc.2022.953149 |
Ejemplares similares
-
Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review
por: Raimondi, Alessandra, et al.
Publicado: (2020) -
MON-356 Atypical Femur Fracture with Denosumab
por: Mirza, Faryal S, et al.
Publicado: (2020) -
Denosumab-associated Periprosthetic Atypical Femur Fracture: A Case Report
por: Abe, Satomi, et al.
Publicado: (2023) -
Atypical fracture of the femur in a patient using denosumab – a case report
por: Schilcher, Jörg, et al.
Publicado: (2014) -
Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone
por: Gaston, Czar Louie, et al.
Publicado: (2016)